Quarterly report pursuant to Section 13 or 15(d)

7. SEGMENTS

v3.4.0.3
7. SEGMENTS
3 Months Ended
Mar. 31, 2016
Segment Reporting [Abstract]  
7. SEGMENTS

The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. The Company also operates two FDA-licensed source plasma collection facilities located in Georgia through ADMA BioCenters.  The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM, is its President and Chief Executive Officer.

 

The plasma collection center segment includes the Company’s operations in Georgia.  The research and development segment includes the Company’s plasma development operations in New Jersey.

 

Summarized financial information concerning reportable segments is shown in the following tables:

 

Three Months Ended   Plasma Collection     Research and              
March 31, 2016   Centers     Development     Corporate     Consolidated  
                         
Revenues   $ 2,088,178     $ -     $ 35,708     $ 2,123,886  
                                 
Cost of product revenue     1,266,421       -       -       1,266,421  
                                 
Gross profit     821,757       -       35,708       857,465  
                                 
Loss from operations     (458,662 )     (2,027,712 )     (1,672,162 )     (4,158,536 )
                                 
Other expense     -       -       (453,933 )     (453,933 )
                                 
Loss before income taxes     (458,662 )     (2,027,712 )     (2,126,095 )     (4,612,469 )
                                 
Total assets     2,595,429       -       17,089,491       19,684,920  
                                 
Depreciation and                                
amortization expense     105,189       -       13,204       118,393  

  

Three Months Ended     Plasma Collection     Research and              
March 31, 2015     Center     Development     Corporate     Consolidated  
                           
Revenues     $ 1,484,217     $ -     $ 18,889     $ 1,503,106  
                                   
Cost of product revenue       909,629       -       -       909,629  
                                   
Gross profit       574,588       -       18,889       593,477  
                                   
Loss from operations       (473,506 )     (1,401,723 )     (1,327,108 )     (3,202,337 )
                                   
Other expense       -       -       (403,198 )     (403,198 )
                                   
Net loss       (473,506 )     (1,401,723 )     (1,730,306 )     (3,605,535 )
                                   
Total assets       3,008,050       -       30,919,630       33,927,680  
                                   
Depreciation and amortization                                  
expense       104,917       -       12,205       117,122  

 

The “Corporate” column includes general and administrative overhead expenses.  Property and equipment, net, included in the “Corporate” column above includes assets related to corporate and support functions.